State-by-State CBD Advertising Restrictions

The 2018 Farm Bill federally legalized hemp-derived CBD at or below a small threshold of delta-9 THC by dry weight. That fact gets cited constantly and matters almost not at all for advertisers. The Farm Bill governs cultivation and extraction. It says nothing about finished consumer products or what you can put in an ad.

Once CBD enters a food, beverage, or dietary supplement, the product is technically adulterated under the Federal Food, Drug, and Cosmetic Act, regardless of its THC content. The Farm Bill created no carve-out for finished consumer goods. The FDA has maintained, consistently, that CBD cannot be introduced into the food supply or marketed as a dietary supplement until that pathway is formally established, which it has not been. Warning letters from the agency track this position with uncomfortable regularity. [Source: FDA Warning Letters database, fda.gov]

The practical ceiling is clear: any claim suggesting a product treats, cures, or mitigates a disease or condition turns that product into an unapproved drug. Hard stop. But federal law provides no usable floor. No permitted claims list, no advertising safe harbor, no uniform standard. States have filled that vacuum, and they have filled it with fifty entirely different answers.

That raises an important question: if federal law draws the ceiling but refuses to specify the floor, who decided where the floor actually sits? Not Congress. Not the FDA, which has spent years declining to finalize rules. The floor was built, state by state, by legislators and regulators who were often working from different premises with different political pressures and, in some cases, openly different ideas about what CBD is. The result is what you get when fifty different jurisdictions each solve the same problem independently: a patchwork so inconsistent it occasionally contradicts itself within a single regional market — like a quilt stitched by fifty people who never agreed on a pattern, and each one is convinced they are the only one who got it right.

Section 781 and What the 2025 Federal Redefinition Means for Advertisers Before November 2026

On November 12, 2025, Section 781 was enacted as part of H.R. 5371. The advertising implications are not obvious until you follow the logic to its end, so it is worth doing that carefully.

Section 781 redefines hemp not by delta-9 THC concentration in the raw plant material but by total THC content in the finished product. For anything intended for ingestion, inhalation, or topical application, the threshold is 0.4 milligrams of total THC per container. The U.S. Hemp Roundtable estimates that over 90% of current CBD products on the market exceed that limit. [Source: U.S. Hemp Roundtable analysis, as cited in trade coverage of H.R. 5371] A single hemp gummy typically contains between 2.5 and 10 milligrams of THC. The math is not subtle.

But here is the part that should unsettle anyone running a compliant campaign: Section 781 also includes a "marketed to have similar effects" clause. A product falls outside the hemp definition based on how its advertising copy characterizes its effects, even if the product itself sits below the 0.4 milligram threshold. That makes ad copy a variable in product eligibility. A reformulated product, carefully brought under the limit, is pulled back outside the legal definition by a single line of copy that implies THC-adjacent effects. Advertising language is no longer just a compliance question. It is a product classification question — which means a copywriter now holds the same power over a product's legal status as a chemist does.

The effective date is November 12, 2026. The Hemp Planting Predictability Act (H.R. 7024, introduced in January 2026 with bipartisan sponsors including Senators Klobuchar, Paul, and Merkley) would defer that date to 2028, but as of this writing it has not passed. The current state-by-state framework remains operative.

The practical posture right now: build your compliance process against current state law, mark November 2026 as a potential hard reset, and watch whether H.R. 7024 actually moves. If Section 781 takes effect without legislative delay and without product reformulation, a large portion of the current CBD catalog loses its legal hemp status entirely. The advertising problem, already considerable, becomes secondary to a product eligibility problem that makes the advertising question moot for everything that no longer qualifies as hemp.

How the FTC Enforces CBD Advertising Claims Independently of the FDA

One of the more persistent misconceptions in this space is that FDA compliance and FTC compliance are essentially the same exercise. They are not, and conflating them is expensive.

The FDA cares about the product. The FTC cares about the claim. Think of it this way: the FDA is the bouncer checking what is in the bottle, while the FTC is the one reading every word on the label. FTC jurisdiction attaches to advertising regardless of whether the underlying product has cleared any other regulatory hurdle, and the evidentiary standard for health claims is strict: human clinical trials are required for any disease-related assertion about CBD. Preclinical data does not meet the bar. Customer testimonials do not meet the bar. "Many customers report" falls short. Operation CBDeceit, which ran from 2020 to 2023, established the enforcement template, and the FTC has been adding to it since. [Source: FTC press releases on Operation CBDeceit, ftc.gov]

In December 2025, the FTC returned $27.6 million to over 1.2 million consumers harmed by deceptive subscription billing tied to CBD and wellness products. [Source: FTC press release, December 2025, ftc.gov] That action is worth reading as a signal. The FTC is not exclusively focused on efficacy claims; billing practices, subscription enrollment, and consumer disclosure are all within scope. Advertisers who have carefully scrubbed their health claims while running aggressive subscription funnels should understand they have addressed one exposure and ignored another.

Joint FTC and FDA cease-and-desist letters in 2024 and 2025 specifically targeted products packaged to visually evoke Froot Loops, Cap'n Crunch, Flamin' Hot Cheetos, Skittles, and Sour Patch Kids. [Source: FTC and FDA joint enforcement announcements, 2024–2025] Packaging and visual presentation are now scrutinized alongside written claims. An ad does not need to say anything false; it just needs to present the product in a way that implies it is something it is not.

The 2023 FTC Endorsement Guides are fully operative for CBD advertising. [Source: FTC Endorsement Guides, 16 CFR Part 255, revised 2023] Every material connection between a brand and an influencer, including payments, free product, and business relationships, requires clear disclosure.

It is also worth considering what this means structurally for multi-channel campaigns. A brand can satisfy state law, satisfy platform acceptance criteria, and still face FTC enforcement because a claim was not substantiated or an influencer relationship was not disclosed. These are parallel requirements, not alternatives. Getting two out of three right is, legally speaking, still wrong.

States Where CBD Advertising Is Effectively Prohibited Regardless of Product Legality

Some states have simplified the calculation considerably, which is one way to put it. The more accurate framing: they have made compliant advertising essentially impossible, and no amount of careful copy review changes that.

Idaho requires zero THC, derived from specific plant parts, with zero tolerance for advertising that implies cannabis legality within the state. The product and the advertisement are both enforcement targets, simultaneously and independently.

Kansas presents a similar structure. CBD is technically legal but must originate from a state-licensed facility and contain no THC. All products require labeling that discloses all contents, CBD purity, and a consumption hazard warning. Any advertising that omits those elements or overstates legality violates state law. The conditions cannot be satisfied in a standard ad format. It is not that the rules are strict; it is that the rules were not designed with advertising in mind at all.

Nebraska is technically in transition and practically unavailable. Hemp farming is licensed. As of June 2025, the Nebraska Medical Cannabis Commission has begun licensing medical cannabis businesses under emergency regulations. But advertising and marketing guidelines have not been finalized; the permanent rulemaking process is ongoing. There is no compliant framework to work within because the framework has not been written yet. That is a different kind of prohibition, but the operational result is the same.

Wyoming prohibits cannabis-related entities from advertising across all media forms. Promotion is restricted to individuals holding a valid medical marijuana certification, which eliminates consumer-facing paid advertising as a category.

Texas is a narrow exception to a broad prohibition. Cannabis is illegal in nearly all contexts. Limited advertising is permitted only through entities authorized under the Texas Compassionate-Use Program, a carve-out so restrictive that most CBD advertisers will not qualify.

The common thread is that the restriction targets the existence of advertising in this category, not merely its content. There is nothing to solve creatively here. Exclude these states from targeting before any other compliance question gets asked.

States with Conditional Advertising Pathways and What Triggers Compliance Failure in Each

A second tier of states permits CBD advertising under conditions specific enough that compliance failure is almost always a technical error rather than a substantive one. Brands that get in trouble here are rarely making wild efficacy claims. They are tripped up by audience composition data they did not retain, a mascot that became a problem only after someone at the state agency decided it was, a price that appeared in a footer, or a disclaimer present but in a font that did not satisfy the specification.

Alabama prohibits television, radio, and billboard promotion of medical cannabis. Online marketing must block direct promotional messaging to anyone under 19. Hemp-derived CBD advertising is permitted but cannot assert medical benefits without FDA approval, a stricter trigger than the FTC standard, since that FDA approval pathway does not currently exist. The effective result is that any health-adjacent claim fails automatically.

Alaska requires that advertising contain no cartoons, mascots, or imagery that attracts minors; no billboards or public signage; and online ads that are not visible to audiences outside Alaska. Social media and website content requires age verification to 21. Each condition is independently enforceable. Violating any one of them while satisfying the others still constitutes a violation.

Illinois applies a 30% audience threshold under the Cannabis Regulation and Tax Act. Advertisements are not permitted on platforms where more than 30% of the audience is under 21. Digital marketing is permitted but requires age-gating. Misleading statements, medical claims, and branding that appeals to minors are all prohibited. The threshold creates an audience verification obligation that persists for every placement, not just at campaign launch.

Pennsylvania restricts pricing, potency information, and product imagery in advertisements while requiring specific health warnings. Those restrictions are not individually exotic, but together they eliminate most standard ad formats. Satisfying them requires building creative from the ground up for the state, not adapting national creative to it.

What satisfies Illinois does not necessarily satisfy Pennsylvania, and building a creative that satisfies both simultaneously is a genuine production problem, not a legal technicality. Multi-state campaigns in this tier require state-level customization as a baseline assumption, not an exception.

States Where Broader Advertising Is Permitted and What "Permissive" Still Requires

"Permissive" is a relative term here. It means compliant advertising is possible. It does not mean the rules disappear.

California represents the most developed permissive framework. Advertising is permitted if at least a strong majority of the audience is reasonably expected to be 21 or older. Medical claims remain prohibited. Cannabis flower can appear in advertisements, a meaningful distinction from most states. Food and beverage CBD is now permitted under California's state hemp rules, subject to manufacturing registration, testing, and labeling requirements; intoxicating hemp derivatives are separately restricted.

But that majority-audience threshold is, in practice, an audience verification infrastructure requirement. It cannot be satisfied through broad publisher buys or standard social placements. It requires verifiable audience data, which pushes compliant advertising toward programmatic platforms with age-verified inventory. The state is permissive in principle and demanding in execution. That gap is where compliance failures happen.

California's framework is, by the standards of this category, the model other states should follow: clear thresholds, documented requirements, predictable enforcement. It is also worth acknowledging that "the most workable framework in this category" is still significantly more burdensome than advertising alcohol, tobacco, or most other regulated consumer goods.

State permission to advertise does not constitute substantiation for a health claim. A California-compliant ad that asserts efficacy without clinical evidence is still vulnerable to FTC enforcement. These are parallel questions, not sequential ones.

And then there is the platform layer, which does not coordinate with any of this.

How Platform Bans Interact with State Law to Produce the Actual Advertising Landscape Brands Operate In

Google, Meta, and TikTok maintain category-level bans on CBD advertising. These bans are enforced algorithmically. They do not consult state law. A brand in California with a fully compliant product and a fully compliant advertisement is still rejected at the platform level. The product's legal status, the ad's compliance with state requirements, the FTC disclosures: none of it matters to the algorithm.

Platform enforcement is not legally required by any state or federal rule. It reflects the platforms' own risk calculus around ad review liability and regulatory ambiguity. Because the federal framework is unresolved and state law varies dramatically, the platforms concluded that categorical exclusion is simpler than case-by-case review. That calculus persists even where underlying law has clarified, because clarification in some states does not resolve the ambiguity the platforms are actually managing at scale.

What remains available: programmatic networks with verified age-gating that can satisfy state audience thresholds; native advertising on publisher sites; email to opted-in lists; influencer content with proper FTC disclosures; SEO-driven organic search; and in some states, out-of-home placements where state law permits. Brands have built significant audience reach through these channels. But they are fewer channels than would exist without platform bans, and each one requires active management rather than standard campaign infrastructure.

Why exactly does this matter structurally? Because when your available channels are already constrained, every remaining channel is load-bearing. Losing one to a preventable violation is not a footnote; it is a meaningful percentage of your reachable audience, gone — like having only three lifeboats and choosing to leave one untied.

Section 781 adds another variable. If most current CBD products lose their legal hemp status in November 2026, platform bans become largely irrelevant for the majority of the current catalog. The advertising restriction problem does not get solved; it gets eclipsed by a product eligibility problem that makes the advertising question moot for products that no longer qualify as hemp. That is a bad outcome, but it is a clarifying one.

Building a State-Aware Compliance Process That Holds Up as the Rules Keep Changing

The layers change on different timelines. Platform policies shift without notice. States finalize regulations that were pending for years, sometimes overnight. Federal definitions get rewritten. A compliance review from 2024 is already partially outdated; the post-Section 781 environment will require another full audit regardless of what was built before it. There is no single review that holds up across this environment, and anyone who sold you one was being optimistic at your expense.

What holds up is a process that checks each layer independently.

Start with geo-exclusion before creative. Idaho, Kansas, Wyoming, and effectively Nebraska and Texas under current rules belong outside the targeting layer before any other question is asked. There is no creative solution for a state where the advertising category is prohibited. Do not spend creative resources solving a geographic problem.

From there, audit every claim against the FTC's clinical-evidence standard, not just state law. State permission to run an ad does not make a claim substantiated. Every assertion, explicit or implied, needs to survive that standard independently. This is the most common place where advertisers who have done their state homework still end up exposed.

For states with audience composition thresholds, retain the data used to qualify the placement. Enforcement in this tier frequently turns on whether the advertiser can demonstrate, after the fact, that they verified audience composition at the time of placement. Build that documentation into the buying process, not as an afterthought after something goes wrong.

Influencer and affiliate disclosure is not optional at any scale. The 2023 FTC Endorsement Guides require clear disclosure of all material connections. Build that language into contracts before anything is published, not after.

Watch Section 781 legislative developments with the seriousness they deserve. The November 2026 effective date is a hard deadline. If the Hemp Planting Predictability Act or a Farm Bill successor does not pass and products are not reformulated to the 0.4 milligram threshold, the advertising strategy that exists today needs to be rebuilt around whatever remains inside the legal hemp definition. That is not a background task.

The brands navigating this successfully are not doing so because they found a loophole or got a good legal opinion. They are doing so because they built a process that treats product eligibility, state advertising law, FTC claim standards, and platform acceptance criteria as four separate questions, evaluated independently, with documented outputs, updated each time a new rule takes effect. Not elegant. Not efficient. But in a regulatory environment this stubbornly inconsistent, it is the only thing that actually works.